Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32681668 | 0.90 | HPGD (0.43) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL28184794 | 0.90 | HPGD (0.43) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL78026 | 0.90 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL31543328 | 0.89 | USP2 (0.41) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL71597 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2NR1H2 | |
| SCHEMBL31566523 | 0.85 | USP2 (0.39) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL2218857 | 0.83 | USP2 (0.41) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL4210880 | 0.82 | USP2 (0.50) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL29317042 | 0.81 | USP2 (0.41) | USP2SMN1; SMN2CYP11B2USP30SCD5 | |
| SCHEMBL29007949 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2CYP11B2USP30HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, DRD3, ARRB1 | USP2 2208/4885SMN1; SMN2 2087/4885CYP11B2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.